2007

Regulatory Affairs

• Seasons Greetings, A. D'Emanuele
• [RegAffairs]QC reporting to production, Globepharm /MAnisfeld
• [RegAffairs]RE: QC reporting to production, Tilak-Kumar Sha
  • <Possible follow-up(s)>
  • [RegAffairs]Re: QC reporting to production, Yongliang Tou
  • [RegAffairs]RE: QC reporting to production, Rick Flora
  • [RegAffairs]Re: QC reporting to production, bruce berger
  • [RegAffairs]Re: QC reporting to production, TJMULLINS
  • [RegAffairs]Re: QC reporting to production, Jim Tyrrell
  • [RegAffairs]Re: QC reporting to production, Ketan Agravat
  • [RegAffairs]Re: QC Reporting to Production, Jean-Denis Mallet
• [RegAffairs]UK Reg Affairs Professional Societies, Globepharm /MAnisfeld
• [RegAffairs]RE: UK Reg Affairs Professional Societies, Lassoff, Peter
• [RegAffairs]Neomycin and Bacitracin topical aerosol, Bojan
• [RegAffairs]Re: Neomycin and Bacitracin topical aerosol, Globepharm /MAnisfeld
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Neomycin and Bacitracin topical aerosol, Zdravko Mauko, FARMAVITA
• [RegAffairs]Black eye for US Pharma Industry, Globepharm /MAnisfeld
• [RegAffairs]Re: Black eye for US Pharma Industry, Malcolm Ross
• [RegAffairs]Mutual Recognition Procedure - TGA & EMEA, thirumurugan gopalasamy
• [RegAffairs]RE: Mutual Recognition Procedure - TGA & EMEA, Steve Binysh
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Jim Tyrrell
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, thirumurugan gopalasamy
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Brian MATTHEWS
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Steve Binysh
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Brian MATTHEWS
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, thirumurugan gopalasamy
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Jim Tyrrell
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Jim Tyrrell
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Steve Binysh
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Jim Tyrrell
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Steve Binysh
  • [RegAffairs]Re: Mutual Recognition Procedure - TGA & EMEA, Hahn, Klaus
• [RegAffairs]Translation of patient questionnaire, Ruthy Batish
• [RegAffairs]Re: Mutual Recognition Procedure - TGA & EME, Malcolm Ross
• [RegAffairs]Sunset Clause in France, Nicola Nestor
• [RegAffairs]Submitting US dossier to EU, Rajaneesh.br
• [RegAffairs]Re: Submitting US dossier to EU, Lassoff, Peter
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Submitting US dossier to EU, Malcolm Ross
  • [RegAffairs]Re: Submitting US dossier to EU, lt09
  • [RegAffairs]Re: Submitting US dossier to EU, Jim Tyrrell
• [RegAffairs]Re: Sunset Clause in France, Malcolm Ross
• [RegAffairs]Labelling, sekhar chandu
• [RegAffairs]Holding time and mean kinetic temperature, Aleksandra
• [RegAffairs]Re; Labelling problems for less developed markets, Steve Binysh
• [RegAffairs]Re: Labelling, rajaneesh B R
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Labelling, sekhar chandu
• [RegAffairs]Re: Holding time and mean kinetic temperature, aks
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Holding time and mean kinetic temperature, Kate
  • [RegAffairs]Re: Holding time and mean kinetic temperature, aks
• [RegAffairs]SA Clinical trials, Swapnil Salaskar
• [RegAffairs]Re: Number of subjects for Clinical trials in SA, shakeel
• [RegAffairs]Holding Time and Kinetic Mean Temperature, Lassoff, Peter
• [RegAffairs]EU GMP certification, Kirti Rawal
• [RegAffairs]Re: EU GMP certification, Brian MATTHEWS
  • <Possible follow-up(s)>
  • [RegAffairs]RE: EU GMP certification, Ketan Agravat
  • [RegAffairs]RE: EU GMP certification, Steve Binysh
  • [RegAffairs]Re: EU GMP certification, Jim Tyrrell
  • [RegAffairs]Re: EU GMP certification, williex52-aa
  • [RegAffairs]Re: EU GMP certification, Ketan Agravat
  • [RegAffairs]Re: EU GMP certification, Brian MATTHEWS
  • [RegAffairs]Re: EU GMP certification, Ketan Agravat
  • [RegAffairs]Re: EU GMP certification, Kirti Rawal
• [RegAffairs]Re: Holding Time and Kinetic Mean Temperature, Malcolm Ross
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Holding Time and Kinetic Mean Temperature, Aleksandra
  • [RegAffairs]Re: Holding Time and Kinetic Mean Temperature, Lassoff, Peter
  • [RegAffairs]Re: Holding Time and Kinetic Mean Temperature, Kate
• [RegAffairs]Medication guide, PAKHI RUSIA
• [RegAffairs]Reg Requirements for US shipping to Israel, Gerry Hara
• [RegAffairs]Re: Reg Requirements for US shipping to Israel, Malcolm Ross
• [RegAffairs]Excipient DMF, Frank w
• [RegAffairs]Re: Excipient DMF, Sreejith_Kurup
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Excipient DMF, Vamsikanth A
  • [RegAffairs]Re: Excipient DMF, NiravChokshi
  • [RegAffairs]Re: Excipient DMF, Malcolm Ross
  • [RegAffairs]Re: Excipient DMF, Yongliang Tou
• [RegAffairs]OTC Products - Schedule??, thirumurugan gopalasamy
• [RegAffairs]Re: OTC Products - Schedule??, Rick Flora
  • <Possible follow-up(s)>
  • [RegAffairs]Re: OTC Products - Schedule??, thirumurugan gopalasamy
• [RegAffairs]Analytical method for unspecified & total impurities, rajaneesh B R
• [RegAffairs]Re: Analytical method for unspecified & totalimpurities, Malcolm Ross
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Analytical method for unspecified & totalimpurities, Frank w
  • [RegAffairs]Re: Analytical method for unspecified & totalimpurities, Yongliang Tou
• [RegAffairs]RE:Analytical method for unspecified & totalimpurities, rajaneesh B R
• [RegAffairs]Site representative, Yongliang Tou
• [RegAffairs]Methotrexate (MTX) in Cell Bank, Leanne Amitzi
• [RegAffairs]Amoxicillin Trihydrate - MRL (Maximum Residue Limit)and ADI (Acceptable Daily Intake)"., Satish Kapoor
• [RegAffairs]Labelling Requirement, Susan Jeffrey
• [RegAffairs]Re: Labelling Requirement], lee.bridgen
• [RegAffairs]Re: Labelling Requirement, lt09
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Labelling Requirement, Vincent Kuanyin Agoth Wek
• [RegAffairs]Residual Levels of Methotrexate, Leanne Amitzi
• [RegAffairs]Re: Residual Levels of Methotrexate, Frank W
• [RegAffairs]Lanthanum salts as finished dosage forms, sanjay shetgar
• [RegAffairs]Same molecule, multiple strengths, multipleapplication nos., kams
• [RegAffairs]Re: Same molecule, multiple strengths, multiple, Hatice Atkaya
• [RegAffairs]Data exclusivity, Hatice Atkaya
• [RegAffairs]Re: Data exclusivity, lee.bridgen
  • <Possible follow-up(s)>
  • [RegAffairs]Re: Data exclusivity, Malcolm Ross
• [RegAffairs]I™LT : Data exclusivity, Hatice Atkaya
• [RegAffairs]RE: ITLT : Data exclusivity, Steve Binysh
• [RegAffairs]RE: Same molecule, multiple strengths, multipleapplication nos., Globepharm /MAnisfeld